Tetrahydrofuran-2-carbonsaeureaethylamid | 36737-88-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: Tetrahydrofuran-2-carbonsaeureaethylamid
• 英文别名: tetrahydro-furan-2-carboxylic acid ethylamide；N-ethyloxolane-2-carboxamide
• CAS: 36737-88-9
• 化学式: C₇H₁₃NO₂
• mdl: MFCD03374914
• 分子量: 143.186
• InChiKey: VOBRGWOZWWAFSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Modulators of muscarinic receptors
  申请人：Davies Robert

  公开号：US20070213315A1

  公开（公告）日：2007-09-13

  The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

  本发明涉及毒蕈碱受体调节剂。本发明还提供包含此类调节剂的组合物，并使用这些方法治疗毒蕈碱受体介导的疾病。
• Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands
  申请人：Cheng Yun-Xing

  公开号：US20100113502A1

  公开（公告）日：2010-05-06

  Compounds of formulae I, or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 and R 3 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  化合物I的公式，或其药学上可接受的盐：其中R1、R2和R3如规范中所定义，以及包括这些化合物的盐和药物组合物已被制备。它们在治疗中很有用，特别是在疼痛管理方面。
• Modulators of Muscarinic Receptors
  申请人：Davies Robert

  公开号：US20120196857A9

  公开（公告）日：2012-08-02

  The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

  本发明涉及毒蕈碱受体的调节剂。本发明还提供包含这种调节剂的组合物，并且提供了使用这些组合物治疗毒蕈碱受体介导疾病的方法。
• Biaryl kinase inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10246469B2

  公开（公告）日：2019-04-02

  The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.

  本公开涉及可抑制 AAK1（适配体相关激酶 1）的式（I）双芳基化合物、包含此类化合物的组合物及其用于治疗疼痛、阿尔茨海默病、帕金森病和精神分裂症等疾病的用途。
• BIARYL KINASE INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20190040080A1

  公开（公告）日：2019-02-07

  The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.